A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution

Diffuse large B-cell lymphoma (DLBCL) patients with high Ki-67 expression receive limited benefits from R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy. This study aims to compare the R-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubici...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jia-Jia, Xia, Yi, Wang, Yu, Liu, Pan-Pan, Bi, Xi-Wen, Sun, Peng, Lin, Tong-Yu, Jiang, Wen-Qi, Li, Zhi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173055/
https://www.ncbi.nlm.nih.gov/pubmed/27183909
http://dx.doi.org/10.18632/oncotarget.9271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173055/
https://www.ncbi.nlm.nih.gov/pubmed/27183909
http://dx.doi.org/10.18632/oncotarget.9271

Ejemplares similares